{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:29:32Z","timestamp":1781522972258,"version":"3.54.1"},"reference-count":31,"publisher":"Korea Disease Control and Prevention Agency","issue":"5","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ophrp.org"],"crossmark-restriction":true},"short-container-title":["PHRP"],"published-print":{"date-parts":[[2022,10,31]]},"abstract":"<jats:p>Objectives: This study aimed to identify potential safety signals and adverse events following the primary Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccination series among children and adolescents aged 5 to 17 years in the Republic of Korea.Methods: Adverse events reported through the COVID-19 vaccination management system (CVMS, a web-based passive vaccine safety surveillance system) and adverse events and health conditions collected from a text message-based survey were analyzed.Results: A total of 14,786 adverse events among 5- to 17-year-old children and adolescents were reported in the CVMS; 14,334 (96.9%) were non-serious and 452 (3.1%) were serious, including 125 suspected cases of acute cardiovascular injury and 101 suspected cases of anaphylaxis. The overall reporting rate was lower in 5- to 11-year-old children (64.5 per 100,000 doses) than in 12- to 17-year-old adolescents (300.5 per 100,000 doses). The text message survey identified that local and systemic adverse events after either dose were reported less frequently in 5- to 11-year-old children than in 12- to 17-year-old adolescents (p&lt;0.001). The most commonly reported adverse events were pain at the injection site, myalgia, headache, and fatigue\/tiredness.Conclusion: The overall results are consistent with the results of controlled trials; serious adverse events were extremely rare among 5- to 17-year-old children and adolescents following Pfizer-BioNTech COVID-19 vaccination. Adverse events were less frequent in children aged 5 to 11 years than in adolescents aged 12 to 17 years.<\/jats:p>","DOI":"10.24171\/j.phrp.2022.0233","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:08:35Z","timestamp":1665727715000},"page":"382-390","update-policy":"https:\/\/doi.org\/10.24171\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years"],"prefix":"10.24171","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-6353","authenticated-orcid":true,"given":"Seontae","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-2737","authenticated-orcid":true,"given":"Yeseul","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-4890","authenticated-orcid":true,"given":"Soon-Young","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-149X","authenticated-orcid":true,"given":"Do Sang","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-2093","authenticated-orcid":true,"given":"Enhi","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-455X","authenticated-orcid":true,"given":"Yeon-Kyeng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"31909","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116298"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2107456"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034577"},{"key":"ref4","volume-title":"Press release: authorization for the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) [Internet]","year":"2021"},{"key":"ref5","volume-title":"Press release: age expansion to use of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) [Internet]","year":"2021"},{"key":"ref6","volume-title":"Press release: authorization for the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) for children aged 5 to 11 years old [Internet]","year":"2022"},{"key":"ref7","volume-title":"National immunization program: 2021 the 19th Korea Advisory Committee on Immunization Practices (KACIP) [Internet]","year":"2021"},{"key":"ref8","volume-title":"Press release: adolescents (16-17 years old) and pregnant women vaccination start from today (October 18, regular briefing) [Internet]","year":"2021"},{"key":"ref9","volume-title":"National immunization program: 2022 the 5th Korea Advisory Committee on Immunization Practices (KACIP) [Internet]","year":"2022"},{"key":"ref10","volume-title":"Press release: initiation of primary series vaccination for children (5-11 years old) and additional vaccination for adolescents (12-17 years old) [Internet]","year":"2022"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.10.011"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18505"},{"key":"ref13","volume-title":""},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-057313"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7031e1"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.24171\/j.phrp.2021.0310"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1967"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.878081"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00791-7"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.24110"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101102"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00059-5"},{"key":"ref23","volume-title":"COVID-19: myocarditis and pericarditis after mRNA COVID-19 vaccination [Internet]","year":"2021"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm705152a1"},{"key":"ref25","volume-title":"Adverse events among children ages 5-11 years after COVID-19 vaccination: updates from v-safe and the Vaccine Adverse Event Reporting System (VAERS) [Internet]","author":"Su","year":"2021"},{"key":"ref26","volume-title":"Comirnaty and Pfizer-BioNTech COVID-19 vaccine [Internet]","year":"2021"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7045e1"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7027e2"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1635"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1866"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00091-1"}],"container-title":["Osong Public Health and Research Perspectives"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ophrp.org\/upload\/pdf\/j-phrp-2022-0233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ophrp.org\/journal\/view.php?doi=10.24171\/j.phrp.2022.0233","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ophrp.org\/upload\/pdf\/j-phrp-2022-0233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T04:38:05Z","timestamp":1666931885000},"score":1,"resource":{"primary":{"URL":"http:\/\/ophrp.org\/journal\/view.php?doi=10.24171\/j.phrp.2022.0233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.24171\/j.phrp.2022.0233","relation":{},"ISSN":["2210-9099","2233-6052"],"issn-type":[{"value":"2210-9099","type":"print"},{"value":"2233-6052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"2022-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-14","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}